Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors Journal Article


Authors: Peart, M. J.; Smyth, G. K.; Van Laar, R. K.; Bowtell, D. D.; Richon, V. M.; Marks, P. A.; Holloway, A. J.; Johnstone, R. W.
Article Title: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
Abstract: Histone deacetylase inhibitors (HDACis) inhibit tumor cell growth and survival, possibly through their ability to regulate the expression of specific proliferative and/or apoptotic genes. However, the HDACi-regulated genes necessary and/or sufficient for their biological effects remain undefined. We demonstrate that the HDACis suberoylanilide hydroxamic acid (SAHA) and depsipeptide regulate a highly overlapping gene set with at least 22% of genes showing altered expression over a 16-h culture period. SAHA and depsipeptide coordinately regulated the expression of several genes within distinct apoptosis and cell cycle pathways. Multiple genes within the Myc, type β TGF, cyclin/cyclin-dependent kinase, TNF, Bcl-2, and caspase pathways were regulated in a manner that favored induction of apoptosis and decreased cellular proliferation. APAF-1, a gene central to the intrinsic apoptotic pathway, was induced by SAHA and depsipeptide and shown to be important, but not essential, for HDACi-induced cell death. Overexpression of p16INK4A and arrest of cells in G1 can suppress HDACi-mediated apoptosis. Although p16INK4A did not affect the genome-wide transcription changes mediated by SAHA, a small number of apoptotic genes, including BCLXL and B-MYB, were differentially regulated in a manner consistent with attenuated HDACi-mediated apoptosis in arrested cells. We demonstrate that different HDACi alter transcription of a large and common set of genes that control diverse molecular pathways important for cell survival and proliferation. The ability of HDACi to target multiple apoptotic and cell proliferation pathways may provide a competitive advantage over other chemotherapeutic agents because suppression/loss of a single pathway may not confer resistance to these agents. © 2005 by The National Academy of Sciences of the USA.
Keywords: controlled study; protein expression; human cell; histone deacetylase inhibitor; validation process; polymerase chain reaction; cell proliferation; proteins; cell death; cells, cultured; cell cycle; gene overexpression; protein bcl 2; apoptosis; gene expression; gene expression profiling; small interfering rna; rna, small interfering; gene function; genetic transcription; caspase; gene expression regulation; gene number; enzyme inhibitors; quantitative analysis; gene identification; vorinostat; hydroxamic acids; gene control; real time polymerase chain reaction; cycline; protein structure; cyclin dependent kinase; histone deacetylases; cell cycle g1 phase; depsipeptides; oncogene myc; histone deacetylase; leukemia cell line; tumor necrosis factor; depsipeptide; apoptotic protease activating factor 1; apoptotic protease-activating factor 1; protein p16ink4a; fr 901228
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Volume: 102
Issue: 10
ISSN: 0027-8424
Publisher: National Academy of Sciences  
Date Published: 2005-03-08
Start Page: 3697
End Page: 3702
Language: English
DOI: 10.1073/pnas.0500369102
PUBMED: 15738394
PROVIDER: scopus
PMCID: PMC552783
DOI/URL:
Notes: --- - "Cited By (since 1996): 250" - "Export Date: 24 October 2012" - "CODEN: PNASA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Paul Marks
    186 Marks